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Abstract 25 
Antibiotics have revolutionised the treatment of infectious disease and improved the 26 
lives of billions of people worldwide over many decades. With the rise in 27 
antimicrobial resistance (AMR) and corresponding lack of antibiotic development, we 28 
find ourselves in dire need of alternative treatments. Bacteriocins are a class of 29 
bacterially produced, ribosomally synthesised, antimicrobial peptides that may be 30 
narrow or broad in their spectrums of activity. Animal models have demonstrated the 31 
safety and efficacy of bacteriocins in treating a broad range of infections, however, 32 
one of the principal drawbacks has been their relatively narrow spectra as compared 33 
with small molecule antibiotics.  In an era where we are beginning to appreciate the 34 
role of the microbiota in human and animal health, the fact that bacteriocins cause 35 
much less collateral damage to the host microbiome makes them a highly desirable 36 
therapeutic.  This review makes a case for the implementation of bacteriocins as 37 
therapeutic antimicrobials, either alone or in combination with existing antibiotics to 38 
alleviate the AMR crisis and to lessen the impact of antibiotics on the host 39 
microbiome.   40 
Abbreviations used: AAD, Antibiotic Associated Diarrhoea; AMR, 41 
Antimicrobial Resistance; AOM, Acute Otitis Media; CDAD, Clostridium difficile 42 
Associated Disorder; CDC, Centres for Disease Control and Prevention; EcN, 43 
Escherichia coli Nissle; GI, Gastrointestinal tract; MIC, Minimum Inhibitory 44 
Concentration ;VRE, Vancomycin Resistant Enterococci.  45 
Introduction 46 
Antimicrobial resistance (AMR) has been recognised as one of the major threats to 47 
public health in the 21st century. In a report commissioned by the UK government in 48 
2014, it was estimated that AMR could be responsible for 10 million deaths 49 
worldwide by 2050, with a global financial cost of $100 trillion (1). Meanwhile the 50 
Centers for Disease Control and Prevention (CDC) estimates the annual cost of AMR 51 
in the US to range from $20 billion in direct healthcare costs to $35 billion in 52 
additional costs to society due to lost productivity (2). Apart from the human and 53 
financial costs associated with AMR, there are also ethical considerations that need to 54 
be addressed surrounding how we as a society respond and deal with the AMR crisis 55 
(3). There are multiple reasons for the present AMR crisis, but significant factors 56 
include the incorrect/indiscriminate administration and use of antibiotics and a dry 57 
antibiotic development pipeline (4, 5). The CDC also recently estimated that in the 58 
US approximately 50% of antibiotics are incorrectly prescribed. Moreover, the use of 59 
antibiotics in agriculture has continued, despite undeniable evidence that this practice 60 
adds to the antimicrobial resistance crisis.  Resistance to a key “last-resort” antibiotic, 61 
colisitin, has been observed in the US, Europe and Asia (6-8). We have also seen the 62 
rapid spread of resistance to another “last resort” class of antibiotics, the carbapenems 63 
(9). With the emergence of these new resistant strains and the emergence of pan-64 
resistant bacteria, it is safe to say we have truly arrived in the much predicted post-65 
antibiotic era (10). 66 
 67 
It is important that we acknowledge that broad-spectrum antibiotic therapy has 68 
revolutionised the treatment of infectious diseases within the last century, but we must 69 
also admit to unintended consequences of antibiotic use, such as potentially negative 70 
effects on the host microbiome and their potential toxicity (5, 11). Although the field 71 
of microbiome research is in its infancy relative to that of antibiotic therapy, evidence 72 
strongly suggests that the composition of the microbiome can be an indicator of health 73 
and is likely to be involved in many aspects of human health and disease (12). Strides 74 
in DNA sequencing technology and bioinformatics have increased our understanding 75 
of the role of the microbiome in a variety of disease states. Indeed the administration 76 
of antibiotics in early life and the subsequent disruption of the microbiota may 77 
contribute to risk of obesity in later life (13, 14). Furthermore, when subjected to 78 
broad-spectrum antibiotic therapy, non-target commensal microbes may evolve and/or 79 
acquire resistance mechanisms to evade the effects of the antibiotic, thereby 80 
contributing to the antibiotic resistance crisis.  81 
 82 
Bacteriocins represent a class of powerful antimicrobial peptides that may provide at 83 
least part of a solution to the AMR crisis. We aim to demonstrate their efficacy in the 84 
treatment of infectious disease and their reduced impact on the host microbiome by 85 
comparison to broad-spectrum antibiotic therapy.    86 
 87 
Bacteriocins: potent antimicrobial peptides 88 
Many excellent reviews have been written about bacteriocins  (11, 15, 16) , but in 89 
brief they are a diverse group of peptides that may be classified into three distinct 90 
groups; class I (modified), class II (unmodified or cyclic) and Class III (>10kDa 91 
peptides). Apart from their potent antimicrobial activity (with minimum inhibitory 92 
concentrations [MIC’s] often in the nanomolar range) they have also been shown to 93 
have antiviral (17), anticancer (18) and immunomodulatory properties (19). 94 
Bacteriocins typically have a narrow spectrum of activity, but broad-spectrum 95 
peptides are also present in this class of antimicrobials (e.g. nisin and lacticin 3147 96 
inhibit a wide range of Gram-positive bacteria). As a result these peptides may be 97 
suitable for treating infections of unknown aetiology, using broad-spectrum 98 
bacteriocins, or may allow more precise targeting of known infectious agents using 99 
highly active narrow spectrum bacteriocins. Bacteriocins are gene encoded, which 100 
makes them amenable to genetic alterations to improve functional characteristics. 101 
Furthermore, their toxicity is low and they may be administered as either purified 102 
peptide or produced in situ by bacteriocin producing probiotic bacteria (11). 103 
Bacteriocins are also known to interact with a variety of receptors, which are different 104 
to those targeted by antibiotics, making cross-resistance less likely (20). Although a 105 
more targeted approach may still ultimately lead to resistance development in the 106 
infectious agent, it does reduce the likelihood of resistance development in 107 
commensal populations outside of the target range of the bacteriocin. Resistance 108 
mechanisms involving the class II receptors, the mannose phosphotransferase system 109 
(Man-PTS), have been identified (21) along with a variety of resistance mechanisms 110 
to the class I lantibiotics (22).  111 
 112 
The microbiota perspective 113 
The term “superorganism” or “holobiont” has commonly been applied to describe the 114 
relationship that exists between humans and its commensal microbes and viruses (23). 115 
Understanding the role of the microbiota in health and protecting its diversity during 116 
the treatment of infectious disease is a key element of why bacteriocins may be 117 
suitable as alternatives to antibiotics.   118 
 119 
The two-peptide sactibiotic bacteriocin, Thuricin CD, is a narrow spectrum 120 
bacteriocin. Thuricin CD is highly active against one of the main causative agent of 121 
antibiotic associated diarrhoea (AAD), Clostridium difficile, which is responsible for 122 
20-30% of AAD cases (24). Briefly, AAD is caused by a disruption of the microbiota 123 
(often referred to as dysbiosis) following broad spectrum antibiotic treatment, and 124 
notably has a recurrence rate of 15-60% (25). Thuricin CD was shown to exhibit 125 
comparable activity to both vancomycin and metronidazole (two antibiotics used for 126 
the treatment of AAD which has progressed to C. difficile associated disease, CDAD). 127 
Importantly, it showed almost no effect on microbial diversity when compared to both 128 
metronidazole and vancomycin in a distal colon model (26). The modified R-Type 129 
bacteriocin, Av-CD291.2, has also been shown to prophylactically prevent 130 
colonization of C. difficile in a mouse model without perturbing the microbiota (27). 131 
There are other broad spectrum bacteriocins which are attractive therapeutic agents by 132 
virtue of their activity against C. difficile, but while the broad spectrum lantibiotic 133 
lacticin 3147 is effective at killing C. difficile, it has a significant impact on the 134 
resident microbiome populations such as Bifidobacterium, Lactobacillus and 135 
Enterococcus species (28). It has also been shown that a commercially available 136 
product containing the lantibiotic nisin, Nisaplin®, can eliminate a C. difficile 137 
infection when added at a concentration of 20X MIC in a simulated human colon 138 
model. However a significant decrease in the total microbiota count was observed, 139 
with Gram-positives being adversely affected (29).  140 
 141 
Notably, in recent years the emergence of Vancomycin Resistant Enterococci (VRE) 142 
has become a great concern and therefore raises the issues surrounding the efficacy of 143 
treating CDAD with vancomycin if it presents a risk to the general population and the 144 
spread of antibiotic resistance. In this light, the treatment of CDAD with bacteriocins 145 
could be a valuable alternative to vancomycin. When VRE development has taken 146 
place, it has been shown that mice colonised with VRE can be decolonized through 147 
the use of an Enterococcus probiotic containing a conjugation defective plasmid 148 
which produces a bacteriocin named Bac-21 (30).  149 
 150 
A defensin-like bacteriocin, bactofencin A, displays in vitro activity against L. 151 
monocytogenes and S. aureus (31, 32). Although one might expect this medium to 152 
broad spectrum antimicrobial peptide to cause drastic changes in the host 153 
microbiome, this was in fact not the case and it was observed that the bactofencin 154 
peptide only subtly modulated an ex vivo host microbiome (distal colon model) when 155 
introduced as a bacteriocin producing probiotic or purified peptide. While the purified 156 
peptide resulted in higher levels of beneficial microbes such as Bifidobacterium, it 157 
was also associated with lower levels of Clostridium, which has been linked to 158 
obesity and gut pathogenesis. Interestingly, although bactofencin does not show 159 
inhibitory activity in vitro against strains from the genera Clostridium, Fusobacterium 160 
and Bacteroides, the reduction of these populations in the bactofencin treated faecal 161 
samples indicates that the consequence of bactofencin altering the overall microbiota 162 
structure impacts, directly or indirectly, on these normally insensitive populations 163 
when in the gut environment (33). 164 
 165 
It has also been shown, using bacteriocin producing probiotic strains and their 166 
isogenic mutants, that the production of bacteriocins can aid the colonisation of a 167 
murine host  (34). Sequencing data revealed that although bacteriocin production by 168 
the probiotics did not affect bacterial diversity at the phylum level, broad spectrum 169 
bacteriocins (enterocins and garvicin ML) had a more significant impact on the 170 
genus/family diversity of the host microbiome than narrow spectrum bacteriocins 171 
(sakacin A, plantaricins and pediocin PA-1).   172 
 173 
Bacteriocins in animal models 174 
Bacteriocins have been shown to be effective in the treatment of variety of infectious 175 
bacteria using two delivery methods, either as purified peptides (Table 1) or when 176 
delivered in situ by probiotics.  177 
 178 
It has been hypothesized that there are three mechanisms by which bacteriocins 179 
mediate their producers probiotic properties (42); (i) Competitive Inhibition: 180 
bacteriocins may support colonization of the host through competitive inhibition of 181 
the autologous microbiota, (ii) Pathogen Inhibition: bacteriocins may interact 182 
directly on a pathogenic target, or (iii) Immunomodulation: bacteriocins may act as 183 
signalling peptides, recruiting other bacteria or recruiting immune cells to the site of 184 
infection to aid elimination of the pathogen (Figure 1). 185 
 186 
Preventing infection 187 
 188 
The concept of oral replacement therapy is another interesting example of 189 
prophylactic probiotic therapy, which has been investigated using the mutacin 1140 190 
producing streptococcus mutans BCS3-L1. This bacteriocin producing strain is 191 
suitable for replacement therapy as it has reduced cariogenic potential because it does 192 
not produce lactic acid, mediated through the removal of its entire lactic acid 193 
dehydrogenase operon (43). Another interesting probiotic that has shown promise in 194 
the limitation of dental caries, plaque accumulation and acidification is Streptococcus 195 
salivarius M18. This strain has 3 plasmid and 1 chromosomally encoded bacteriocins, 196 
which is perhaps why it can colonise the oral cavity so effectively. It also produces 197 
two enzymes, urease and dextranase, which reduce saliva acidity and counteract 198 
plaque formation (44). In a clinical trial, both the safety and efficacy of this strain’s 199 
probiotic potential was demonstrated, and it was shown to significantly reduce plaque 200 
formation in subjects who received the probiotic, over those who received the placebo 201 
(45). Furthermore, the treatment of children who have a high risk of dental caries 202 
development, with an oral formulation of the S. salivarius M18 probiotic (Carioblis®) 203 
was shown to reduce the likelihood of new dental caries development (46).  204 
 205 
It has been demonstrated that dosing mice orally with the bacteriocin producer Lb. 206 
salivarius UCC118 three days prior to infection with L. monocytogenes resulted in a 207 
significant reduction in subsequent infection by L. monocytogenes (47). Nisin Z and 208 
pediocin AcH have also been shown to reduce and prevent the colonisation of a 209 
mouse model with vancomycin resistant Enterococci (VRE), where the 210 
bacteriocinogenic probiotic was administered 8 days prior to infection (48). It has also 211 
been demonstrated using a porcine model that Salmonella enterica serovar 212 
typhimurium shedding is reduced and disease symptoms of infection are alleviated 213 
when  a mix of five probiotic strains was administered 6 days before infection (49). 214 
One of the probiotics, L. salivarius, produces salivaricin P, which can kill the other 4 215 
strains in the probiotic mix.  Interestingly, this bacteriocinogenic strain dominated in 216 
the ileum (the primary attachment site of the infecting Salmonella) whereas it was 217 
only detected as a minor component in the faeces of the same animals.  This suggests 218 
that bacteriocin production may play a role where colonisation can occur along the 219 
gastrointestinal (GI) tract (50). The concept of using prophylactic probiotics to 220 
competitively colonise a pathogens niche could be an effective strategy in agriculture 221 
to reduce antibiotic usage. If, as expected, regulations limiting the use of antibiotics in 222 
agriculture come into force, probiotics may be invaluable alternative.  223 
 224 
Acute otitis media (AOM) is a type of inflammatory disease of the middle ear, 225 
characterised typically by rapid inflammation, potential tympanic membrane 226 
perforation, along with fullness and erythema. It has been reported that the levels of 227 
normal α-haemolytic Streptococcus colonising the nasopharynx of otitis prone 228 
children is much lower than in healthy individuals and that recolonization can 229 
significantly reduce the episodes of AOM (51, 52). It has been demonstrated treating 230 
otitis prone children with a history of AOM, with a nasal spray containing safe 231 
Streptococcus salivarius 24SMB (a strain which produces a bacteriocin-like 232 
substance), reduces the incidences of AOM over the placebo treated group (53).  233 
 234 
Treating infection 235 
 236 
Helicobacter pylori infection and colonisation results in a variety of disease states and 237 
may even lead to the development of gastric carcinoma. More recently, the prevalence 238 
of antibiotic resistant H. pylori has been increasing, creating a need for a new 239 
therapeutic agent (54). It has been shown in mice that eradication of H. pylori was 240 
achieved using a bacteriocinogenic probiotic treatment of P. acidilactici BA28 (55). 241 
Using a mixture of cranberry juice and the bacteriocin producing probiotic culture 242 
Lactobacillus johnsonii str. La1 supernatant, the carriage of H. pylori was also 243 
reduced in children after three weeks of treatment (56).  244 
 245 
One barrier to the use of probiotics as a therapeutic is their ability to survive and 246 
colonise the area of infection. It has been shown that Pediococcus acidilactici UL5 247 
and Lactococcus lactis ATCC 11454 can produce the bacteriocins pediocin PA-1 and 248 
nisin, respectively, in situ under simulated upper gastric conditions (57). Interestingly, 249 
the in vitro activity of a bacteriocin does not always correspond to the in vivo activity, 250 
where the bacteriocin is sometimes more or less active in an animal model, as is the 251 
case with mersacidin which is more active in vivo than in vitro (58).  252 
 253 
Bacteriocins against Gram-negatives 254 
Comparatively speaking, Gram-negative bacteria are relatively insensitive to 255 
bacteriocins compared to their Gram-positive counterparts, largely owing to the outer 256 
membrane which acts as a physical barrier. Until recently the treatment of Gram-257 
negative infections with bacteriocins has not been favoured due to the efficacy of 258 
conventional antibiotics in the treatment of these infections. The rise of antibiotic 259 
resistant Gram-negative bacteria to the last line of antibiotics (6) means the treatment 260 
of Gram-negative infections using bacteriocins can no longer be ignored .  261 
 262 
Widespread use requires a solution to the relative insensitivity of Gram-negative 263 
microorganisms. One possibility is to use bacteriocins in combination with other 264 
antimicrobial agents, including conventional antibiotics. Although conventional 265 
antibiotics will have an impact on the host microbiota (as previously discussed), 266 
certain bacteriocin/antibiotic combinations can be synergistic (59-62) and therefore 267 
lead to a reduced dose of both antimicrobial agents needed to treat an infection, 268 
thereby lowering the potential effect on the host microbiome, the cytotoxic effects on 269 
the host and may potentially reduce the development of resistance.  270 
 271 
Success of antibiotics is also hindered by Gram-negative bacteria residing within 272 
biofilms, where they are highly resistant to antibiotic treatments. Bacteriocin/ 273 
antibiotic combinations have shown great promise in overcoming biofilm mediated 274 
resistance for important Gram-negative pathogens such as Pseudomonas aeruginosa 275 
(63) and Escherichia coli (64).  276 
 277 
Although this review mainly focuses on Gram-positive bacteriocins, it is important to 278 
also to identify Gram-negative bacteriocins which may have potential therapeutic 279 
significance. Microcins are ribosomally-synthesized peptides commonly produced by 280 
Gram-negative bacteria which are active against Gram-negative strains, and are an 281 
interesting alternative to Gram-positive bacteriocins. They have been shown to 282 
display potent antimicrobial activity in vitro (65, 66) and more recently also in vivo 283 
(67). It has been demonstrated that the microcin producer E. coli Nissle 1917 (EcN) 284 
can prevent colonisation of competing Enterobacteriaceae in the gut, whilst still 285 
having a minimal impact on the diversity of the gut microbiota. However, EcN 286 
microcins exhibit their mechanism of action by targeting specific siderophore 287 
receptors on other Enterobacteriaceae which are only displayed during iron 288 
starvation, making their spectrum of activity quite narrow. Additionally to its 289 
prophylactic applications, EcN has also been demonstrated to reduce inflammation 290 
and weight loss associated with Salmonella infections. Another microcin produced by 291 
E. coli G3/10, microcin S, has been shown to inhibit other E. coli strains and 292 
furthermore can prevent the adherence of Enteropathogenic E. coli (EPEC) to 293 
intestinal epithelial cells (68).  294 
 295 
Overcoming the limitations/outlook 296 
In previous decades significant emphasis was placed on functional characteristics of 297 
bacteriocins, such as spectrum of activity, pH and temperature stability, which were 298 
essential for the use of bacteriocins in food applications. For their use as therapeutics 299 
additional characteristics such as proteolytic resistance, stability and solubility of 300 
bacteriocins will also be important. 301 
 302 
With advancements in the field of bioengineering many intrinsic limitations have 303 
been overcome, and it has been shown using the prototypic lantibiotic, nisin, that 304 
bioengineering strategies can improve functional qualities such as antimicrobial 305 
activity (69-72), solubility (73, 74) diffusion properties (75) and effectiveness against 306 
Gram-negative bacteria (71). Indeed, similar bioengineering strategies could be 307 
applied to other bacteriocins once suitable expression systems have been developed. 308 
Although the sensitivity of bacteriocins to proteolytic cleavage was previously 309 
regarded as a desirable trait when using these peptides as food preservatives, it does 310 
represent a major concern with regard to their administration and widespread use, 311 
both orally and intravenously. Bioengineering strategies could be once again used to 312 
manipulate peptide residues so they are no longer recognisable by host proteases and 313 
therefore are not proteolytically cleaved, thereby improving peptide functional 314 
qualities (76). Notably, the therapeutic application of the prototypic bacteriocin, nisin, 315 
has been in part hampered by its sensitivity to host proteases (77. Other approaches 316 
include prospecting for bacteriocins that display innate resistance to proteases, as was 317 
achieved with pseudomycoicidin (78), which is naturally resistant to trypsin due to the 318 
presence of a thioether ring structure. The field of bioinformatics and the use of such 319 
programs as BAGEL 3.0 (79) and antiSMASH (80) could be a fundamental aspect of 320 
this prospecting, as these bacteriocin amino acid prediction tools from genome 321 
sequences may also allow researchers to identify protease resistant peptides before 322 
investing large amounts of time and effort in characterising such bacteriocins. Finally, 323 
understanding bacteriocin pharmacodynamics and pharmacokinetics are also essential 324 
to their safe implementation as therapeutics, which has been under investigated in 325 
comparison to other aspects of bacteriocin research. If bacteriocins are indeed to 326 
become an alternative to conventional antibiotics, a greater emphasis must be placed 327 
on research surrounding these host-drug interactions, such as was achieved with 328 
MU1140 (81). Addressing these limitations of bacteriocin research to date could 329 
provide a turning point for the flagging interest of the pharmaceutical industry and 330 
make bacteriocins an attractive therapeutic alternative to current antibiotics (10).  331 
 332 
Although there is considerable evidence that narrow spectrum bacteriocins have a 333 
minimal effect on the host microbiome by comparison to current broad-spectrum 334 
antibiotics, it should also be recognised that more work in this regard is needed to 335 
strengthen the argument for the use of bacteriocins as antibiotics, along with 336 
overcoming the previously outlined limitations. Ultimately, we believe given the safe 337 
history of use of bacteriocins in food and the large body of literature surrounding this 338 
field, that they are useful candidates for antimicrobial therapeutics as the AMR crisis 339 
continues to worsen.  340 
Summary 341 
• Antimicrobial resistance (AMR) is a major threat to public health requiring 342 
immediate attention. 343 
• Bacteriocins are potent antimicrobial peptides, active in the nanomolar range and 344 
have a reduced impact on the host microbiota. 345 
• Bacteriocins may be used to treat a broad range of infections and can be delivered 346 
as purified peptides or as bacteriocinogenic probiotics.  347 
• Combining antibiotics and bacteriocins is a strategy to reduce the negative 348 
impacts on the host microbiota and also alleviate the AMR crisis. 349 
• Overcoming the current limitations of bacteriocin-based therapeutics should be a 350 
key goal of bacteriocin research in the future.   351 
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Figure 1: Bacteriocinogenic probiotics can be utilized either prophylactically or 686 
therapeutically to treat an infection. M, M cell; Mac, macrophage; Mu, mucous; T, 687 
T cell; IEC, intestinal epithelial cell; DC, dendritic cell.  688 

Peptide Strain inhibited Model Purity Reference 
Nisin F S. aureus Immunosuppressed 
Wistar rats 
Semi-pure (35) 
S. aureus  Brushite cement in 
BALB/c mice 
Semi-pure (36) 
Lacticin NK34 S. aureus/  
S. simulans 
ICR mice Semi-pure (37) 
Nisin V L. monocytogenes BALB/c mice Pure (38) 
Divercin V41  L. monocytogenes BALB/c mice Pure (39) 
Mutacin B-Ny266 S. aureus Unknown Pure (40) 
Mersacidin Methicillin-
resistant 
Staphylococcus 
aureus (MRSA) 
BALB/cA mice pure (41) 
Table 1. Bacterial infections in animal models successfully treated using purified 
bacteriocins. 
